AB Science S.A

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. Show More...

  • Website https://www.ab-science.com
  • Sector Healthcare
  • Industry Drug Manufacturers-Specialty & Generic
  • Last Quote 1.17 EUR
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share EUR -0.32 -0.31 -0.34 -0.45 -0.49 -0.78 -0.78 -0.75 -0.69 -0.55 -0.55
    Dividends EUR
    Payout Ratio % *
    Shares Mil 30.0 31.0 32.0 33.0 33.0 34.0 36.0 36.0 38.0 39.0 39.0
    Book Value Per Share * EUR 0.47 0.34 0.15 -0.04 -0.21 -0.36 -0.22 0.59 -0.64 -0.6
    Free Cash Flow Per Share * EUR -0.28 -0.33 -0.2 -0.41 -0.38 -0.64 -0.82 -0.78 -0.77 -0.54
    Return on Assets % -43.64 -32.79 -36.96 -39.7 -43.02 -83.68 -78.47 -61.22 -71.31 -108.11 -108.11
    Financial Leverage (Average) 1.99 3.81 6.12 127.96 4.71
    Return on Equity % -119.93 -85.73 -173.95 -557.67 -899.57
    Return on Invested Capital % -120.8 -85.73 -75.33 -62.84 -146.36
    Interest Coverage -122.21 -15.88 -13.61 -11.87 -21.13 -57.45
    Current Ratio 3.58 2.99 2.88 3.31 2.11 1.74 1.78 2.6 1.08 0.72 0.72
    Quick Ratio 2.54 2.19 2.44 2.8 1.65 1.27 1.02 2.11 0.64 0.41 0.41
    Debt/Equity 1.27 86.95 0.87